OVERVIEW

Assessing Antibiotic Pharmacology and Susceptibility to Guide Selection and Improve Outcomes is organized by Power-Pak C.E. - Continuing Education for Pharmacists & Pharmacy Technicians.

Published Date: June 28, 2019
Expiration Date: June 28, 2020

Credits: 0.75 hour (0.075 ceu)

Goal:
James Lewis, PharmD presents two patient cases relating to the assessment and treatment of serious infections caused by Gram-negative pathogens. A faculty panel from MAD-ID 2019 provide supplemental background and discussions on the application of local antibiotic susceptibility tests, PK/PD drug profiles, and selection of antimicrobial therapy to improve outcomes. The purpose of this activity is to provide pharmacists, who care for patients with serious infections with the latest data on antimicrobial stewardship, available and emerging antibiotics against Gram-negative pathogens, and the optimization of therapy to improve outcomes and reduce resistance.

Educational Objectives:
Upon completion of this activity, participants will be able to:
• Demonstrate an understanding of the molecular epidemiology of antibiotic resistance in bacterial pathogens
• Summarize the salient features and critical differences between the antibiotics currently in development for use against Gram-negative pathogens
• Describe strategies to optimize antimicrobial therapy to ensure effectiveness of antibiotics and reduce resistance

Additional details will be posted as soon as information is available.

Credits
  • 0.75 Hours
  • 0.075 CEU
  • SPECIALITIES

    Pharmacy and Medicine

    RELATED ONLINE COURSES

    Apr 04, 2022 - Nov 30, 2026 | Webcast

    State required course for Alabama ...
    6 AMA PRA Category 1 Credits™
    ...
    More actions
    US$246

    May 16, 2022 - Nov 30, 2026 | Webcast

    State required course for Connecticut
    5 AMA PRA Category 1 Credits™
    ...
    More actions
    US$50.05

    May 16, 2022 - Dec 31, 2027 | Webcast

    State required course for South Carolina
    2 AMA PRA Category 1 Credits™
    ...
    More actions
    US$94.73